GFM
KYMR icon

GF Fund Management’s Kymera Therapeutics KYMR Stock Holding History

GF Fund Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
1,729
+113
+7% +$9.71K ﹤0.01% 274
2026
Q1 		$135K Buy
1,616
+203
+14% +$16.1K ﹤0.01% 311
2025
Q4 		$110K Sell
1,413
-125
-8% -$8.44K ﹤0.01% 338
2025
Q3 		$87.1K Sell
1,538
-120
-7% -$5.41K ﹤0.01% 345
2025
Q2 		$72.4K Hold
1,658
– – ﹤0.01% 389
2025
Q1 		$45.4K Buy
1,658
+298
+22% +$10.9K ﹤0.01% 430
2024
Q4 		$54.7K Buy
+1,360
New +$61.4K ﹤0.01% 382

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GF Fund Management's KYMR Position: Q2 2026 in Review

GF Fund Management increased its Kymera Therapeutics (KYMR) stake by 7% in Q2 2026, buying an estimated $9.71K and bringing the position to 1,729 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

GF Fund Management first reported a position in KYMR in Q4 2024 and has held it in 7 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • GF Fund Management held 1,729 shares of Kymera Therapeutics worth $198K as of Q2 2026.
  • GF Fund Management bought 113 Kymera Therapeutics shares in Q2 2026, an estimated $9.71K.
  • Kymera Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #274 holding.
  • GF Fund Management first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.